Indian glass vials producers said they are gearing up to meet any potential demand arising from pharmaceutical companies to fill their COVID-19 vaccines and drugs. Health experts globally are ...

BERLIN/LONDON, Sept 18 (Reuters) - The medical vials division of Schott AG launched its initial public offering on Monday, aiming for a valuation of up to 4.3 billion euros ($4.59 billion), it ...

Schott AG plans to list its specialty medical ... The division manufactures vials used in mRNA vaccines like the coronavirus inoculations produced by BioNTech SE and Moderna Inc, among other ...

a pharmaceutical glass vial for the filling line performance; SCHOTT Type I plus, a pharmaceutical glass vial for drug formulations; SCHOTT TopLyo, a pharmaceutical glass vial to avoid fogging for ...

After a period of speedy growth, Schott’s pharma business is setting out on its own. Monday, the packaging specialist and technology group revealed it has formally set up a standalone company ...

products to specialty vials. In addition, the ongoing strong demand for glass syringes in the Drug Delivery Systems (DDS) segment compensated for a temporary weaker demand for polymer syringes. SCHOTT ...

In the last few years, Schott has capitalized on market trends, manufacturing vials for COVID-19 mRNA vaccines, such as those made by Moderna and Pfizer/BioNTech. Schott Pharma also is producing ...

and SCHOTT Pharma AG & Co. KGaA (MDAX: 1SXP), announced today that they have entered into a strategic industry alliance ("Alliance for RTU") to support market adoption of Ready-to-Use (RTU) vials ...

The expected stronger growth in DCS will be enabled by high-value solutions, such as coated specialty vials for ADCs and ready-to-use cartridges for GLP-1 drugs, and drugs administered subcutaneously.

SCHOTT Poonawalla, a joint venture between German ... a wide range of advanced containment and delivery systems including vials, prefillable syringes, ampoules, and cartridges for auto-injector ...